



RECEIVED  
NOV 8 1999  
TECH CENTER 1600/2900

RECEIVED  
JAN 05 2000  
6281614

PC9835AJTJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Dwayne Thomas Friesen, et al.

SERIAL NO.: 09/380,825

FILED: September 7, 1999

FOR: Solubilized Sertraline Compositions

Assistant Commissioner For Patents  
Washington, D.C. 20231

Sir:

Examiner: Unknown

Art Unit: 1614

I hereby certify that this TECH CENTER 1600/2900

correspondence is being deposited

with the United States Postal Service

as First Class mail in an envelope

addressed to: Assistant Commissioner

for Patents, Washington, D.C. 20231,

on this 1st day of November 1999

By

INFORMATION DISCLOSURE STATEMENT


Cross Reference To Co-pending Applications

In the matter of the above-identified application, the Examiner is requested to review co-pending U.S. Application No. 09/380,885, 09/380,897, and 09/380,900, all filed on September 7, 1999, pursuant to his/her examination of this application. The application is not listed on an accompanying PTO-FB-A820, nor has a copy of the co-pending application been supplied as it is assumed that the Patent Office has ready access to same.

No fee is thought to be due for this submission as it is being filed within three months of the US Filing Date and/or prior to receipt of the first Office Action in this application. If, however, the Commissioner determines that any fee is due (including any fee for extension, for which petition is hereby made), please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Respectfully submitted,

Date: Nov 1, 1999

  
James T. Jones  
Attorney for Applicants  
Reg. No. 30,561

Pfizer Inc  
Patent Department  
Eastern Point Road  
Groton, Connecticut 06340  
(860)441-490



RECEIVED

JAN 11 2000

PCT 1615

PATENT

PC9824AJTJ

520 Rec'd PCT/PTA 04 NOV 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: William John Curatolo, et al.

SERIAL NO.: 09/380,885

FILED: September 7, 1999

FOR: Delayed-Release Dosage Forms of  
Sertraline

Assistant Commissioner For Patents  
Washington, D.C. 20231

Sir:

Examiner: Unknown

Art Unit: Unknown

I hereby certify that this

correspondence is being deposited

with the United States Postal Service

as First Class mail in an envelope

addressed to Assistant Commissioner

for Patents, Washington, D.C. 20231,

on this 1st day of November 1999

By

INFORMATION DISCLOSURE STATEMENT

Applicants herein make available to the Patent and Trademark Office (PTO) a copy of a form which conforms with PTO-FB-A820 and which lists one or more references thereon.

It is requested the Examiner carefully consider the entire text of each reference pursuant to his/her examination of this application, in accord with 37 CFR 1.104(a). It is believed the Examiner will concur with Applicants' belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing on this application (M.P.E.P. 1302.12).


Cross Reference To Co-pending Applications

In the matter of the above-identified application, the Examiner is requested to review co-pending U.S. Application No. 09/380,825, 09/380,897, and 09/380,900, all filed on September 7, 1999, pursuant to his/her examination of this application. The application is not listed on an accompanying PTO-FB-A820, nor has a copy of the co-pending application been supplied as it is assumed that the Patent Office has ready access to same.

No fee is thought to be due for this submission as it is being filed within three months of the US Filing Date and/or prior to receipt of the first Office Action in this application. If, however, the Commissioner determines that any fee is due (including any fee for extension, for which petition is hereby made), please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Respectfully Submitted,

Date: Nov 1, 1999

  
James T. Jones  
Attorney for Applicants  
Reg. No. 30,561

Pfizer Inc.  
Patent Department  
Eastern Point Road  
Groton, Connecticut 06340  
860-441-4903